Ocular Therapeutix, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$808M
↑+76.5% +$350Mvs FY2024
Total Liabilities
$154M
↑+7.8% +$11Mvs FY2024
Equity
$654M
↑+107.5% +$339Mvs FY2024
Cash
$737M
↑+88.0% +$345Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $808M | $458M |
| Current Assets | $782M | $441M |
| Cash | $737M | $392M |
| ST Investments | $0 | $0 |
| Receivables | $31M | $32M |
| Inventory | $4M | $3M |
| Other Current | $11M | $13M |
| Non-Current Assets | $26M | $17M |
| PPE | $20M | $9M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $6M | $8M |
| Total Liab+Eq | $808M | $458M |
| Current Liab. | $51M | $41M |
| Accounts Payable | $4M | $4M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $128K |
| Other CL | $47M | $37M |
| Non-Current Liab. | $103M | $101M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $103M | $101M |
| Equity | $654M | $315M |
| Retained Earnings | $1.16B | $891M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · OCUL · Comparing FY2025 vs FY2024